From StructContinue beyond “Tempus AI’s disclosed web runs from Illumina to AstraZeneca to a crowded rival fieldBack to the brief ↗Feed / ILMN

Illumina, Inc.

ILMN

Healthcare · 206.45 +2.6% today

You’ve read what changed. Here’s whether the market is confirming it.

Isolated · not yet confirmedMarket checked 11 Sept, 15:55 GMT-4

Market read

Illumina, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 22 directly disclosed connections are confirming.

Company+2.6% todayVolume comparison unavailable
Market group0 of 1 activeGenomic Sequencing · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • ILMN's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if ILMN's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Diagnostics & Research

No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 22 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • ILMN's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 16, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations328
Usable filing statements0
Verified relationships9
Evidence supporting the case
  • Operating margin changed +37.6 percentage points in the latest annual period.
  • Net margin changed +47.5 percentage points in the latest annual period.
  • Operating cash flow covered net income at 1.27x in the latest annual period.
Evidence challenging the case
  • Latest annual revenue changed -0.7% year over year.
Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 11, 2026

206.45
6m+78.6%12m+116.2%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2022-01-02$4.5B+39.7%$5.04+2.0%
2023-01-01$4.6B+1.3%$-28.00+4.0%
2023-12-31$4.5B-1.7%$-7.34+0.6%
2024-12-29$4.4B-2.9%$-7.69+0.6%
2025-12-28$4.3B-0.7%$5.45-1.9%

Valuation discipline

Peer-relative valuation withheld

Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

206.45+2.6% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for ILMN. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for ILMN. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind ILMN

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

LABFiling-linked nameinvesteeFeb 12, 2026

SUBSEQUENT EVENTS On January 30, 2026, we acquired SomaLogic and other specified assets from Standard BioTools for a $ 350 million upfront cash payment, subject to customary adjustments.

Depended on by

CDNACareDx, Inc.supplierApr 28, 2026

These sole source suppliers include Thermo Fisher Scientific, Inc., or Thermo Fisher, which supplies us with instruments, laboratory reagents and consumables; Roche Molecular Systems, which supplies us with laboratory reagents and consumables; Hamilton Roboti…

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 20 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

ILMN is currently a Leader in the organic co-movement group Genomic Sequencing. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for ILMN; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.